Lindahl G
Microbiol Mol Biol Rev. 2020; 85(1).
PMID: 33239435
PMC: 7709521.
DOI: 10.1128/MMBR.00078-20.
Lei L, Yang Y, Tran K, Wang Y, Chiang C, Ozorowski G
Cell Rep. 2019; 27(2):586-598.e6.
PMID: 30970260
PMC: 6458978.
DOI: 10.1016/j.celrep.2019.03.039.
Burioni R, Mancini N, De Marco D, Clementi N, Perotti M, Nitti G
PLoS One. 2008; 3(10):e3423.
PMID: 18923648
PMC: 2565497.
DOI: 10.1371/journal.pone.0003423.
Martin G, Sun Y, Heyd B, Combes O, Ulmer J, Descours A
Virology. 2008; 381(2):241-50.
PMID: 18835005
PMC: 2645002.
DOI: 10.1016/j.virol.2008.08.039.
Cenna J, Tan G, Papaneri A, Dietzschold B, Schnell M, McGettigan J
Vaccine. 2008; 26(50):6405-14.
PMID: 18804506
PMC: 2629409.
DOI: 10.1016/j.vaccine.2008.08.069.
A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.
Crooks E, Moore P, Franti M, Cayanan C, Zhu P, Jiang P
Virology. 2007; 366(2):245-62.
PMID: 17580087
PMC: 2080857.
DOI: 10.1016/j.virol.2007.04.033.
Anticandidal immunity and vaginitis: novel opportunities for immune intervention.
Cassone A, De Bernardis F, Santoni G
Infect Immun. 2007; 75(10):4675-86.
PMID: 17562759
PMC: 2044548.
DOI: 10.1128/IAI.00083-07.
Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.
Witvrouw M, Fikkert V, Hantson A, Pannecouque C, OKeefe B, McMahon J
J Virol. 2005; 79(12):7777-84.
PMID: 15919930
PMC: 1143621.
DOI: 10.1128/JVI.79.12.7777-7784.2005.
Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes.
McKenna P, Pomerantz R, Dietzschold B, McGettigan J, Schnell M
J Virol. 2003; 77(23):12782-94.
PMID: 14610200
PMC: 262580.
DOI: 10.1128/jvi.77.23.12782-12794.2003.
Evolution of two amino acid positions governing broad neutralization resistance in a strain of feline immunodeficiency virus over 7 years of persistence in cats.
Pistello M, Matteucci D, Giannecchini S, Bonci F, Sichi O, Presciuttini S
Clin Diagn Lab Immunol. 2003; 10(6):1109-16.
PMID: 14607875
PMC: 262447.
DOI: 10.1128/cdli.10.6.1109-1116.2003.
Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.
Srivastava I, Stamatatos L, Kan E, Vajdy M, Lian Y, Hilt S
J Virol. 2003; 77(20):11244-59.
PMID: 14512572
PMC: 224963.
DOI: 10.1128/jvi.77.20.11244-11259.2003.
Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.
Poignard P, Moulard M, Golez E, Vivona V, Franti M, Venturini S
J Virol. 2002; 77(1):353-65.
PMID: 12477840
PMC: 140593.
DOI: 10.1128/jvi.77.1.353-365.2003.
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
Sanders R, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R
J Virol. 2002; 76(17):8875-89.
PMID: 12163607
PMC: 136973.
DOI: 10.1128/jvi.76.17.8875-8889.2002.
Novel monoclonal antibody directed at the receptor binding site on the avian sarcoma and leukosis virus Env complex.
Ochsenbauer-Jambor C, Delos S, Accavitti M, White J, Hunter E
J Virol. 2002; 76(15):7518-27.
PMID: 12097564
PMC: 136349.
DOI: 10.1128/jvi.76.15.7518-7527.2002.
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts.
Giannecchini S, Isola P, Sichi O, Matteucci D, Pistello M, Zaccaro L
J Virol. 2002; 76(14):6882-92.
PMID: 12072489
PMC: 136316.
DOI: 10.1128/jvi.76.14.6882-6892.2002.
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.
Parren P, Geisbert T, Maruyama T, Jahrling P, Burton D
J Virol. 2002; 76(12):6408-12.
PMID: 12021376
PMC: 136210.
DOI: 10.1128/jvi.76.12.6408-6412.2002.
Neutralizing antibodies mechanism of neutralization and protective activity against HIV-1.
Xiao Y, Dong X, Chen Y
Immunol Res. 2002; 25(3):193-200.
PMID: 12018459
DOI: 10.1385/IR:25:3:193.
Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.
Binley J, Sanders R, Master A, Cayanan C, Wiley C, Schiffner L
J Virol. 2002; 76(6):2606-16.
PMID: 11861826
PMC: 135977.
DOI: 10.1128/jvi.76.6.2606-2616.2002.
A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope.
Johnson W, Morgan J, Reitter J, Puffer B, Czajak S, Doms R
J Virol. 2002; 76(5):2075-86.
PMID: 11836385
PMC: 135934.
DOI: 10.1128/jvi.76.5.2075-2086.2002.
Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.
Moore J, Parren P, Burton D
J Virol. 2001; 75(13):5721-9.
PMID: 11390574
PMC: 114288.
DOI: 10.1128/JVI.75.13.5721-5729.2001.